Patisiran sodium, a pioneering therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals.

AiCuris begins a Phase 1 trial for the antiviral drug AIC468 targeting BK virus infections in kidney transplant patients.

Bexagliflozin is a small molecule drug designed to target SGLT2 and is primarily used in the therapeutic areas of endocrinology and metabolic disease.

JCR Pharmaceuticals has begun the initial dosing for the Phase I clinical trial of JR-441 targeting Mucopolysaccharidosis Type IIIA.

Inclisiran sodium is a novel small interfering RNA (siRNA) therapeutic developed by Alnylam Pharmaceuticals and commercialized by Novartis.

Numab Therapeutics has begun a Phase 1 clinical trial for the NM32 program targeting patients with solid tumors.

Empagliflozin is a medication used primarily to treat type 2 diabetes and, in some cases, to help manage heart failure.

ProMIS Neurosciences Shares Encouraging Results from Phase 1a Trial of PMN310 at the 17th Alzheimer’s Disease Clinical Trials Conference.

Cemdisiran, a groundbreaking therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals in collaboration with Sanofi.

Biomea Fusion has released preclinical findings indicating that Icovamenib (BMF-219) improves the efficacy of GLP-1 therapies.

When discussing pan-KRAS inhibitors, it’s essential to mention RMC-6236, developed by Revolution Medicines.

Kither Biotech has revealed the start of a Phase 1 clinical trial for KIT2014, an innovative inhaled peptide treatment for cystic fibrosis.